Clinical Study of Plasmodium Immunotherapy for Advanced Breast Cancers and Advanced Liver Cancers
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Plasmodium immunotherapy CAS Lamvac Biotech (Primary)
- Indications Advanced breast cancer; Liver cancer
- Focus Adverse reactions
- Sponsors CAS Lamvac Biotech
Most Recent Events
- 17 Feb 2024 Planned End Date changed from 31 Dec 2021 to 30 Jun 2026.
- 21 Mar 2018 New trial record